CVRX News and Press, CVRx Inc. From 04/09/25

2025-04-09 08:45:06 ET Summary CVRx Inc. stock has recently dropped 40%, presenting a buying opportunity as the long-term growth potential remains intact. Barostim has strong clinical results and significant market potential, with a $2.2 billion TAM. Average selling prices can...

2025-04-07 17:44:32 ET More on CVRx CVRx, Inc. (CVRX) Q4 2024 Earnings Conference Call Transcript CVRx targets $63M-$65M revenue in 2025 with strengthened sales strategy CVRx GAAP EPS of -$0.43 misses by $0.05, revenue of $15.3M beats by $0.08M Seeking Alpha&...

MINNEAPOLIS, April 07, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced certain preliminary unaudited first quarter 2025 revenue results. “While we continue to make significant progress in driving adoption of Barost...

2025-03-03 14:56:36 ET More on iShares U.S. Medical Devices ETF IHI: Multiples Have Climbed Despite Stubborn Rates Healthcare sector takes the lead in 2025 as market volatility rises Top SA Quant-rated medical devices stocks as technicals look strong Seeking ...

2025-02-26 16:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2025-02-19 10:00:00 ET Summary In 2024, the Mairs & Power Small Cap Fund was up 7.25%, slightly underperforming the S&P Small Cap 600 Total Return benchmark. While we were disappointed with the modest underperformance, we are encouraged that stock selection was positive du...

MINNEAPOLIS, Feb. 12, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc . (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today the presentation of new real-world evidence at the Technology and Heart Failure Therapeutics (THT) conference in Boston. The st...

2025-02-04 23:00:46 ET More on CVRx CVRx, Inc. (CVRX) Q4 2024 Earnings Conference Call Transcript CVRx GAAP EPS of -$0.43 misses by $0.05, revenue of $15.3M beats by $0.08M CVRx upgraded by William Blair to outperform Seeking Alpha’s Quant Rating on CV...

2025-02-04 23:00:22 ET CVRx, Inc. (CVRX) Q4 2024 Earnings Conference Call February 04, 2025 04:30 PM ET Company Participants Mike Vallie - Investor Relations, ICR Healthcare Kevin Hykes - President & Chief Executive Officer Jared Oasheim - Chief Financial Off...

2025-02-04 16:17:05 ET More on CVRx CVRx: Impressive Top-Line Growth Seems Priced In CVRx upgraded by William Blair to outperform CVRx says total Q4 revenue is expected to be between $15.2M and $15.3M Seeking Alpha’s Quant Rating on CVRx Histor...